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ABSTRACT
Introduction Avelumab, an antiprogrammed death 
ligand-1 antibody, is approved as a monotherapy for 
treatment of metastatic Merkel cell carcinoma and 
advanced urothelial carcinoma, and in combination with 
axitinib for advanced renal cell carcinoma. We report the 
efficacy and safety of first- line avelumab in advanced non- 
small cell lung cancer (NSCLC).
Methods In a phase I expansion cohort of the JAVELIN 
Solid Tumor trial, patients with treatment- naive, metastatic, 
or recurrent NSCLC received 10 mg/kg avelumab 
intravenously every 2 weeks. Endpoints included best 
overall response, duration of response (DOR), progression- 
free survival (PFS), overall survival (OS), and safety.
Results Overall, 156 patients were enrolled and treated. 
Median duration of follow- up was 18.6 months (range, 15 
to 23 months). The objective response rate was 19.9% 
(95% CI, 13.9 to 27.0), including complete response in 
3 (1.9%) and partial response in 28 (17.9%). Median 
DOR was 12.0 months (95% CI, 6.9 to not estimable). 
Median PFS was 4.0 months (95% CI, 2.7 to 5.4) and 
the 6- month PFS rate was 38.5% (95% CI, 30.7 to 46.3). 
Median OS was 14.1 months (95% CI, 11.3 to 16.9) and 
the 12- month OS rate was 56.6% (95% CI, 48.2 to 64.1). 
Treatment- related adverse events (TRAEs) occurred in 107 
patients (68.6%), including grade ≥3 TRAEs in 19 (12.2%). 
Immune- related adverse events and infusion- related 
reactions occurred in 31 (19.9%) and 40 patients (25.6%), 
respectively. No treatment- related deaths occurred.
Conclusion Avelumab showed antitumor activity with 
a tolerable safety profile as a first- line treatment in 
patients with advanced NSCLC. These data support further 
investigation of avelumab in the phase III JAVELIN Lung 
100 study.
Trial registration details  ClinicalTrials. gov 
NCT01772004; registered January 21, 2013.
INTRODUCTION
Monoclonal antibodies targeting immune 
checkpoint proteins are established treat-
ments for metastatic non- small cell lung 
cancer (NSCLC). In 2016, the antipro-
grammed cell death protein-1 (PD-1) anti-
body pembrolizumab was approved as 
first- line monotherapy for patients with meta-
static NSCLC without targetable epidermal 
growth factor receptor (EGFR) or anaplastic 
lymphoma kinase (ALK) gene defects and 
with ≥50% programmed death ligand 1 (PD- 
L1) expression on tumor cells.1 2 Based on 
results of the phase III KEYNOTE-042 study, 
approval of pembrolizumab monotherapy in 
the first- line setting was expanded in the USA 
for patients with ≥1% PD- L1 expression on 
tumor cells.3 By contrast, in a phase III trial 
of first- line nivolumab (anti- PD-1) mono-
therapy versus platinum- based chemotherapy 
in patients with advanced NSCLC with ≥5% 
PD- L1 expression on tumor cells, nivolumab 
did not significantly improve progression- 
free survival (PFS) or overall survival (OS).4 
More recently, immune checkpoint inhibitors 
(pembrolizumab and atezolizumab) have 
been assessed in combination with chemo-
therapy in the first- line NSCLC setting and 
have shown superior efficacy compared with 
chemotherapy alone in several randomized 
trials.5–7
Avelumab, a human anti- PD- L1 immu-
noglobulin G1 antibody with a wild- type Fc 
region, has been shown in preclinical models 
to induce antitumor activity via adaptive 
and innate effector cells.8 9 Avelumab has 
been approved in some countries as mono-
therapy for metastatic Merkel cell carcinoma, 
as monotherapy for advanced urothelial 
carcinoma that has not progressed with 
platinum- containing chemotherapy (first- 
line maintenance therapy) or following 
disease progression, and in combination 
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with axitinib for first- line treatment of advanced renal 
cell carcinoma.10 11 In previous clinical trials, avelumab 
has demonstrated clinical activity and a tolerable safety 
profile in patients with various other tumor types, 
including platinum- treated NSCLC.12–16 Here, we report 
efficacy and safety data from a phase I expansion cohort 
of the JAVELIN Solid Tumor trial in which patients with 
advanced NSCLC received first- line avelumab. Prelimi-
nary findings from this cohort led to the initiation of the 
phase III JAVELIN Lung 100 study (NCT02576574) of 
first- line avelumab versus platinum- based doublet chemo-
therapy in patients with PD- L1- positive NSCLC.17
MATERIALS AND METHODS
Study design and treatment
JAVELIN Solid Tumor (NCT01772004) is an interna-
tional, multicohort, open- label phase I trial. In this phase 
Ib NSCLC expansion cohort, patients, who were unse-
lected for PD- L1 expression, had histologically confirmed 
stage IV (per International Association for the Study of 
Lung Cancer classification, seventh edition)18 or recurrent 
NSCLC, no prior treatment for metastatic or recurrent 
disease, and no activating EGFR mutation or ALK trans-
location/rearrangement (tumors with non- squamous cell 
histology were tested if mutational status was unknown). 
General eligibility criteria for the JAVELIN Solid Tumor 
trial have been reported previously.12
Procedures and assessments
Patients received avelumab 10 mg/kg by intravenous 
infusion every 2 weeks until disease progression, unac-
ceptable toxicity, or other criteria for withdrawal were 
met. Patients were permitted to continue treatment 
despite progression according to the investigator’s deci-
sion and in agreement with the patient if no new symp-
toms appeared, existing symptoms did not worsen, 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status did not decrease, and the investigator did 
not consider it necessary to administer a salvage therapy. 
Dose reductions were not permitted. Premedication with 
an antihistamine (diphenhydramine or equivalent) and 
acetaminophen was given 30 to 60 min before each infu-
sion. Treatment was permanently discontinued for any 
grade ≥3 adverse event (AE) except for specified tran-
sient AEs (reported previously).12 13 Grade 2 AEs were 
managed by treatment delays of ≤2 subsequent omitted 
doses; events that did not resolve to grade ≤1 or recurred 
resulted in permanent discontinuation of avelumab. Clin-
ical activity and safety were analyzed in all patients who 
received ≥1 dose of avelumab.
Tumor assessments were performed every 6 weeks for 
the first year and every 12 weeks thereafter by investiga-
tors according to Response Evaluation Criteria in Solid 
Tumors 1.1 (RECIST 1.1) and modified immune- related 
response criteria.19 Safety was assessed every 2 weeks at each 
visit, and AEs were graded according to National Cancer 
Institute Common Terminology Criteria for Adverse 
Events V.4.0. Immune- related AEs (irAEs) were identified 
using a prespecified list of Medical Dictionary for Regu-
latory Activities (MedDRA)- preferred terms followed by 
comprehensive medical review. Infusion- related reactions 
(IRRs) were identified using an expanded definition that 
included both a prespecified list of MedDRA- preferred 
terms (IRR, drug hypersensitivity, or hypersensitivity reac-
tion) that occurred post infusion within 48 hours, and 
additional signs or symptoms that occurred on the day of 
infusion and resolved within 2 days.
PD- L1 expression was assessed using a proprietary 
immunohistochemistry assay (PD- L1 IHC 73-10 pharmDx; 
Dako, Carpinteria, California). In previous studies 
comparing the 73-10 PD- L1 assay with the 22C3 assay used 
in pembrolizumab trials, the 73-10 assay showed greater 
sensitivity, and the ≥80% PD- L1 cut- off for the 73-10 assay 
was found to be comparable to the ≥50% PD- L1 cut- off 
for the 22C3 assay (manuscript in press).20 21 PD- L1- 
positive status was predefined as PD- L1 expression of any 
intensity on ≥1% of tumor cells; PD- L1 expression status 
was also assessed using cut- offs of ≥50% and ≥80% in post 
hoc analyzes.
Prespecified endpoints assessed in this expansion 
cohort included confirmed best overall response, dura-
tion of response (DOR), and PFS based on investi-
gator assessment according to RECIST 1.1, best overall 
response based on investigator assessment according to 
modified immune- related response criteria, OS, PD- L1 
expression, and safety (all secondary endpoints in the 
overall JAVELIN Solid Tumor trial protocol).
Statistical analysis
Planned enrollment was 150 patients, which was based 
on the anticipated sample size required to estimate and 
provide 95% Clopper- Pearson CIs for potential objective 
response rates (ORRs). Safety data were summarized 
using descriptive statistics. Time- to- event endpoints were 
estimated using the Kaplan- Meier method, while 95% 
CIs for medians were calculated using the Brookmeyer- 
Crowley method. P values for the association between 
PD- L1 status and ORRs were determined using the Fish-
er’s exact test. Comparisons between other subgroups 
were not prespecified and are reported descriptively.
RESULTS
Patient characteristics and disposition
Between March 18, 2015, and November 19, 2015, 156 
patients were enrolled from seven countries in North 
America, Europe, and Asia (table 1). The median age was 
69.5 years (range, 41 to 90 years), 83 patients (53.2%) 
were male, and most patients (108 (69.2%)) had an 
ECOG performance status of 1. Tumor histology was 
squamous in 46 patients (29.5%) and non- squamous in 
110 (70.5%). A total of 139 patients (89.1%) were ever 
smokers (current or previous) and 17 (10.9%) had never 
smoked. PD- L1 expression was evaluable in 111 patients 
(71.2%), of whom 88 (79.3%) had PD- L1- positive tumors 
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based on a ≥1% cut- off. EGFR and ALK mutation status 
were unknown in 18 (11.5%) and 16 (10.3%), respectively. 
At data cut- off (February 15, 2017), the median follow- up 
was 18.6 months (range, 15 to 23 months). Patients 
received a median of 12 avelumab infusions (range, 
1 to 49) over a median duration of 5.5 months (range, 
0.5 to 22.5 months). At data cut- off, 26 patients (16.7%) 
remained on study treatment. Reasons for permanent 
treatment discontinuation were disease progression (82 
(52.6%)), AEs (24 (15.4%)), withdrawal of consent (9 
(5.8%)), death (9 (5.8%)), and other reasons (6 (3.8%)).
Efficacy
Of 156 patients, 3 (1.9%) had a confirmed complete 
response (CR) and 28 (17.9%) had a confirmed partial 
response (PR), resulting in an ORR of 19.9% (95% CI, 
13.9% to 27.0%); 17 patients (10.9%) were not evalu-
able for response per RECIST (missing evaluations or 
not assessable; table 2). ORRs were observed in 17.4% 
(95% CI, 7.8% to 31.4%) of patients with squamous and 
20.9% (95% CI, 13.7% to 29.7%) of patients with non- 
squamous histology. ORRs in ever smokers and never 
smokers were 20.9% (95% CI, 14.4% to 28.6%) and 
11.8% (95% CI, 1.5% to 36.4%), respectively. In patients 
who had unknown EGFR or ALK mutation status, ORRs 
were 16.7% (95% CI, 3.6% to 41.4%) and 18.8% (95% 
CI, 4.0% to 45.6%), respectively. Of the three patients 
who had a CR, two had a preceding PR. Response was 
ongoing in 15 of 31 patients at data cut- off (figure 1A). 
The median time to response was 11.4 weeks (range, 
5.1 to 29.6 weeks) and the median DOR in patients with 
confirmed responses was 12.0 months (95% CI, 6.93 
months to not estimable). Of 142 patients who were 
evaluable for changes in target lesions (ie, those with 
Table 1 Patient demographics and baseline characteristics
Characteristic N=156
Age
  Median (range), years 69.5 (41 to 90)
  <65, n (%) 51 (32.7)
  ≥65, n (%) 105 (67.3)
Sex, n (%)
  Male 83 (53.2)
  Female 73 (46.8)
Geographic region, n (%)
  North America 127 (81.4)
  Europe 25 (16.0)
  Asia 4 (2.6)
Race, n (%)
  White 124 (79.5)
  Black or African American 12 (7.7)
  Asian 6 (3.8)
  Other 14 (9.0)
ECOG PS, n (%)
  0 46 (29.5)
  1 108 (69.2)
  2* 2 (1.3)
Smoking status, n (%)
  Never used 17 (10.9)
  Regular user 29 (18.6)
  Occasional user 2 (1.3)
  Former user 108 (69.2)
Time since first diagnosis, median (range), 
months
2.0 (0.02 to 143.5)
Time since diagnosis of metastatic 
disease, median (range), months†
1.5 (0.2 to 92.0)
Tumor histology, n (%)
  Squamous cell carcinoma 46 (29.5)
  Non- squamous cell carcinoma 110 (70.5)
EGFR mutation status, n (%)
  Wild type 137 (87.8)
  Mutant‡ 1 (0.6)
  Unknown 18 (11.5)
ALK mutation status, n (%)
  Wild type 140 (89.7)
  Mutant 0
  Unknown 16 (10.3)
KRAS mutation status, n (%)
  Wild type 6 (3.8)
  Mutant 10 (6.4)
  Unknown 140 (89.7)
PD- L1 expression ≥1% of tumor cells, n (%)
  Positive 88 (56.4)
  Negative 23 (14.7)
  Not evaluable§ 45 (28.8)
Continued
Characteristic N=156
PD- L1 expression ≥50% of tumor cells, n (%)
  Positive 53 (34.0)
  Negative 58 (37.2)
  Not evaluable§ 45 (28.8)
PD- L1 expression ≥80% of tumor cells, n (%)
  Positive 38 (24.4)
  Negative 73 (46.8)
  Not evaluable§ 45 (28.8)
*Both patients had an ECOG PS of 1 at baseline, which had increased 
to 2 at the first dose of study treatment.
†Data missing for six patients.
‡This patient was permitted to enroll following discussions between 
the investigator and the sponsor based on expected resistance to 
available tyrosine kinase inhibitor therapy.
§Reasons for PD- L1 expression not being evaluable included tumor 
sample containing insufficient tumor cells (<100), non- evaluable 
sample type (eg, cytology specimen), and no tumor tissue available for 
analysis.
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative 
Oncology Group performance status; EGFR, epidermal growth factor 
receptor; PD- L1, programmed death ligand-1.
Table 1 Continued
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a baseline and on- study tumor assessment available), 
93 (65.5%) had a reduction in tumor size of any level, 
while 43 (30.3%; including 12 patients with unconfirmed 
responses) had ≥30% reduction (figure 1B and online 
additional file 1), with no notable trends based on tumor 
histology or smoking status (online additional file 2). 
The median PFS in all patients was 4.0 months (95% CI, 
2.7 to 5.4 months) and the 6- month PFS rate was 38.5% 
(95% CI, 30.7% to 46.3%) (online additional file 3). 
The median OS was 14.1 months (95% CI, 11.3 to 16.9 
months) and the 12- month OS rate was 56.6% (95% CI, 
48.2% to 64.1%) (online additional file 3).
In analyzes of efficacy in subgroups with PD- L1 expres-
sion levels of ≥1%, ≥50%, and ≥80%, ORRs by RECIST 1.1 
were 19.3% (95% CI, 11.7% to 29.1%), 22.6% (95% CI, 
12.3% to 36.2%), and 26.3% (95% CI, 13.4% to 43.1%), 
respectively (table 3). Patients who were not evaluable for 
PD- L1 status had an ORR of 26.7% (95% CI, 14.6% to 
41.9%). Best change in target lesions by PD- L1 status is 
shown in online additional file 2. In PD- L1+ and PD- L1− 
subgroups (≥1% and <1% cut- offs, respectively), median 
PFS was 4.0 months (95% CI, 2.7 to 6.0 months) and 1.5 
months (95% CI, 1.35 to 5.4 months), and median OS 
was 14.1 months (95% CI, 11.2 to 18.2 months) and 11.3 
months (95% CI, 1.6 to not estimable), respectively.
In analyzes of response by immune- related criteria, 
four additional patients, who did not achieve a response 
according to RECIST 1.1, had an objective response, 
resulting in an immune- related ORR of 22.4%, including 
immune- related CRs in four patients (2.6%) and immune- 
related PRs in 31 patients (19.9%). In PD- L1 subgroups 
with expression levels of ≥1%, ≥50%, and ≥80%, immune- 
related ORRs were 23.9% (95% CI, 15.4% to 34.1%), 
28.3% (95% CI, 16.8% to 42.3%), and 34.2% (95% CI, 
19.6% to 51.4%), respectively. In the overall population, 
median PFS based on immune- related criteria was 6.9 
months (95% CI, 5.4 to 9.7 months).
Safety
AEs (irrespective of relationship to treatment)
In total, 156 patients (100%) had an AE of any grade. 
AEs led to permanent treatment discontinuation in 31 
patients (19.9%). Twenty patients (12.8%) died following 
an AE that was unrelated to treatment; no deaths were 
considered related to treatment. IRR, identified using 
an expanded definition, was the most common AE and 
occurred in 40 patients (25.6%), including grade ≥3 AEs 
in five patients (3.2%). Most IRRs (34 of 40 patients) 
occurred after the first infusion, and eight patients (5.1%) 
permanently discontinued treatment because of an IRR.
Treatment-related AEs
Treatment- related AEs (TRAEs) of any grade occurred 
in 107 patients (68.6%; table 4). Of 19 patients (12.2%) 
Table 2 Best overall response (per RECIST 1.1, based on 
investigator assessment)
Response N=156
Best overall response, n (%)
  Complete response 3 (1.9)
  Partial response 28 (17.9)
  Stable disease 68 (43.6)
  Progressive disease 40 (25.6)
  Not evaluable* 17 (10.9)
ORR (95% CI), % 19.9 (13.9 to 27.0)
Disease control rate, n (%) 99 (63.4)
*Includes patients with no post- baseline assessment (n=9); 
stable disease of insufficient duration (<6 weeks without further 
assessment available; n=4); new therapy started before first post- 
baseline assessment (n=2); non- evaluable assessments (n=1); or 
non- evaluable with progressive disease occurring >12 weeks after 
study assessment (n=1).
ORR, objective response rate; RECIST, Response Evaluation 
Criteria in Solid Tumors.
Figure 1 (A) Time to and duration of response in patients 
with confirmed complete response or confirmed partial 
response (n=31). The first per- protocol scan was performed 
after 6 weeks for the first tumor assessment (week 7). Median 
follow- up was 18.6 months (range, 15 to 23 months). (B) Best 
change from baseline in target lesions in evaluable patients 
(patients with a baseline and at least one post- baseline lesion 
assessment; n=142). *Patient with 415% increase in tumor 
diameter imputed with a cap of 100%.
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who had a grade ≥3 TRAE, three (1.9%) had a grade 4 
TRAE (IRR, pneumonitis, and acute respiratory distress 
syndrome, which each occurred in one patient (0.6%)). 
The only grade 3 TRAEs that occurred in >1 patient 
were IRR (5 (3.2%)) and fatigue (4 (2.6%)). Seventeen 
patients (10.9%) had a TRAE that led to permanent treat-
ment discontinuation (online additional file 4).
Serious TRAEs
Serious TRAEs occurred in 15 patients (9.6%), and the 
most common (≥2 patients) were IRR (4 (2.6%)) and 
pneumonitis (2 (1.3%)).
Immune-related adverse events
Thirty- one patients (19.9%) had an irAE, of which 
one patient (0.6%) had a grade ≥3 irAE (pneumonitis; 
table 5). The most common category was endocrine 
irAEs, which included 15 patients (9.6%) with either 
hypothyroidism or hyperthyroidism, and one patient 
(0.6%) with adrenal insufficiency. In addition, cutaneous 
irAEs, including immune- mediated rash or pruritus, 
occurred in 12 patients (7.7%), pneumonitis occurred in 
five patients (3.2%), and immune- mediated diarrhea or 
colitis occurred in three patients (1.9%).
DISCUSSION
In this study, first- line avelumab monotherapy showed 
clinical activity and an acceptable safety profile in 
patients with treatment- naive advanced NSCLC. The 
ORR was 19.9% and the median DOR was 12.0 months. 
In comparison, ORRs in studies of avelumab in patients 
with platinum- treated advanced NSCLC, who were unse-
lected for PD- L1 status, were 14% in a separate phase I 
cohort of the JAVELIN Solid Tumor trial22 and 15% in the 
phase III JAVELIN Lung 200 trial.23 In the current study, 
patients with ≥50% and ≥80% PD- L1- positive tumors had 
ORRs (by RECIST 1.1) of 22.6% and 26.3%, respectively. 
However, a high proportion of patients (28.8%) were 
not evaluable for tumor PD- L1 expression, and patient 
numbers were low, particularly in the high PD- L1- positive 
subgroup (n=38), which hampers interpretation of the 
biomarker data. In the overall population, the median 
PFS was 4.0 months and the median OS was 14.1 months. 
Response rates and PFS assessed using immune- related 
criteria were slightly increased compared with analyzes 
based on RECIST 1.1. Although the study included small 
subgroups with unknown EGFR and ALK mutation status, 
ORRs in these patients were similar to the ORR in the 
overall population. Safety outcomes were comparable to 
previous studies of avelumab and other anti- PD-1/PD- L1 
agents in NSCLC.4 12 13 22 24–26
Data from this study can be considered in the context 
of similar early- phase studies of other anti- PD-1/PD- L1 
antibodies administered as first- line monotherapy for 
PD- L1- positive NSCLC, although cross- trial comparisons 
should be interpreted with caution as eligibility criteria 
and patient populations may differ, and companion 
assays to detect PD- L1 expression were developed inde-
pendently for each agent. In a cohort of a phase I study 
(KEYNOTE-001) in which patients with treatment- naive 
NSCLC received pembrolizumab, the ORR was 27%, 
median PFS was 6.2 months, and median OS was 22.1 
months; efficacy was increased in patients whose tumors 
had high PD- L1 expression (≥50% of tumor cells PD- L1+ 
using the 22C3 assay, which is comparable to ≥80% 
of tumor cells PD- L1+ using the more sensitive 73-10 
Table 3 ORR according to tumor PD- L1 status (cut- off indicates percentage of tumor cells expressing PD- L1)
PD- L1 positive PD- L1 negative P value
≥1% cut- off
  Patients, n 88 23 –
  ORR (95% CI), % 19.3 (11.7 to 29.1) 8.7 (1.1 to 28.0) 0.353
  Median PFS (95% CI), months 4.0 (2.7 to 6.0) 1.5 (1.4 to 5.4) –
  Median OS (95% CI), months 14.1 (11.2 to 18.2) 11.3 (1.6 to NE) –
≥50% cut- off
  Patients, n 53 58 –
  ORR (95% CI), % 22.6 (12.3 to 36.2) 12.1 (5.0 to 23.3) 0.207
  Median PFS (95% CI), months 5.4 (2.8 to 9.6) 2.4 (1.4 to 2.8) –
  Median OS (95% CI), months 14.2 (11.9 to NE) 13.6 (6.8 to 18.2) –
≥80% cut- off
  Patients, n 38 73 –
  ORR (95% CI), % 26.3 (13.4 to 43.1) 12.3 (5.8 to 22.1) 0.109
  Median PFS (95% CI), months 5.4 (2.7 to 11.1) 2.7 (1.4 to 4.2) –
  Median OS (95% CI), months 14.2 (12.4 to 16.9) 14.0 (8.4 to 19.7) –
NE, not estimable (not reached); ORR, objective response rate; OS, overall survival; PD- L1, programmed death ligand 1 ; PFS, progression- 
free survival.
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assay).24 27 In patients with NSCLC treated with first- line 
nivolumab in the phase I CheckMate 012 trial, the ORR 
was 23%, median PFS was 3.6 months, and median OS was 
19.4 months.25 In addition, in patients with PD- L1- high 
NSCLC (≥25% PD- L1 expression on tumor cells; SP263 
assay) treated with first- line durvalumab in the phase 
I/II 1108 study, the ORR was 27%, median PFS was 5.4 
months, and median OS was 21.9 months.26 Subsequent 
phase III trials of anti- PD-1/PD- L1 antibodies versus 
platinum- based chemotherapy in the first- line NSCLC 
setting have produced conflicting findings. In KEYNOTE-
024 and KEYNOTE-042, pembrolizumab showed superior 
OS versus platinum- based chemotherapy in patients with 
advanced NSCLC with ≥50% and ≥1% PD- L1 expres-
sion on tumor cells, respectively,2 3 which provided the 
basis for the approval of pembrolizumab in this setting. 
Similarly, in the recently reported IMpower110 trial, first- 
line atezolizumab showed superior OS versus platinum- 
based chemotherapy in patients with PD- L1- high NSCLC 
(PD- L1 expression on ≥50% of tumor cells and/or 
≥10% of tumor- infiltrating immune cells; SP142 assay).28 
However, in CheckMate 026, nivolumab did not show 
superior OS versus platinum- based chemotherapy in 
patients with PD- L1- positive tumors (≥5% PD- L1 expres-
sion on tumor cells; 28-8 assay).4 Similarly, in the MYSTIC 
trial, durvalumab alone or in combination with tremeli-
mumab (anticytotoxic T- lymphocyte- associated protein 
4) was not superior to platinum- based doublet chemo-
therapy in patients with PD- L1- high NSCLC (≥25% PD- L1 
expression on tumor cells; SP263 assay).29 More recently, 
several phase III trials have reported superior efficacy for 
anti- PD-1 or anti- PD- L1 antibodies combined with chemo-
therapy versus chemotherapy alone in NSCLC irrespective 
of PD- L1 expression.5–7 However, combination regimens 
may be associated with increased toxicity burden; thus 
checkpoint inhibitor monotherapy with pembrolizumab 
remains a standard first- line treatment for PD- L1- high 
NSCLC.30 31 The ongoing phase III JAVELIN Lung 100 
study (NCT02576574), which was initiated in 2015, is 
assessing first- line avelumab monotherapy compared 
Table 4 TRAEs (any grade in ≥5% of patients or grade ≥3 
in any patient) and IRRs
N=156
Any grade Grade ≥3
Any TRAE, n (%)* 107 (68.6) 19 (12.2)
  Fatigue 32 (20.5) 4 (2.6)
  Nausea 19 (12.2) 0
  Hypothyroidism 14 (9.0) 0
  Diarrhea 12 (7.7) 0
  Chills 11 (7.1) 0
  Decreased appetite 10 (6.4) 1 (0.6)
  Arthralgia 9 (5.8) 0
  Dry skin 9 (5.8) 0
  Pruritus 8 (5.1) 0
  Fever 8 (5.1) 0
  Vomiting 8 (5.1) 0
  Pneumonitis 5 (3.2) 1 (0.6)
  Lipase increased 4 (2.6) 1 (0.6)
  Hypokalemia 2 (1.3) 1 (0.6)
  Hyponatremia 2 (1.3) 1 (0.6)
  Acute respiratory distress 
syndrome
1 (0.6) 1 (0.6)
  Endocrine disorder 1 (0.6) 1 (0.6)
  Hypertension 1 (0.6) 1 (0.6)
  Hypoxia 1 (0.6) 1 (0.6)
  Musculoskeletal chest pain 1 (0.6) 1 (0.6)
  Nephrotic syndrome 1 (0.6) 1 (0.6)
  Pneumothorax 1 (0.6) 1 (0.6)
IRR, n (%)† 40 (25.6) 5 (3.2)
*Incidence of treatment- related IRR based on the single MedDRA 
preferred term is not listed.
†Composite term, which includes AEs categorized as IRR, drug 
hypersensitivity, or hypersensitivity reaction that occurred on the 
day of or day after infusion, in addition to signs and symptoms of 
IRR that occurred on the same day of infusion and resolved within 
2 days (including AEs classified by investigators as related or 
unrelated to treatment).
AE, adverse event; IRR, infusion- related reaction; MedDRA, 
Medical Dictionary for Regulatory Activities; TRAE, treatment- 
related adverse event.
Table 5 Immune- related adverse events (any grade in any 
patient; n=156)
Patients, n (%)
Any grade Grade ≥3
Any immune- related adverse 
event
31 (19.9) 1 (0.6)
Immune- mediated thyroid 
disorder
15 (9.6) 0
  Hypothyroidism 14 (9.0) 0
  Hyperthyroidism 1 (0.6) 0
Immune- mediated rash or pruritus 12 (7.7) 0
  Pruritus 6 (3.8) 0
  Rash 6 (3.8) 0
  Rash maculopapular 2 (1.3) 0
  Pruritus generalized 1 (0.6) 0
  Rash erythematous 1 (0.6) 0
  Rash macular 1 (0.6) 0
Immune- mediated pneumonitis 5 (3.2) 1 (0.6)
Immune- mediated colitis 3 (1.9) 0
  Diarrhea 2 (1.3) 0
  Colitis 1 (0.6) 0
Immune- mediated adrenal 
insufficiency
1 (0.6) 0
Autoimmune disorder 1 (0.6) 0
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with platinum- based doublet chemotherapy in patients 
with PD- L1- positive NSCLC. The primary analysis popu-
lation in the JAVELIN Lung 100 study consists of patients 
with high PD- L1- expressing tumors (≥80% of tumor cells; 
73-10 assay); hence, this study will provide an assessment 
of avelumab in a patient population similar to those of 
earlier trials of anti- PD-1/PD- L1 monotherapy.
In summary, the results from this phase Ib study showed 
that avelumab monotherapy has clinical activity and 
acceptable safety as a first- line treatment for patients with 
advanced NSCLC, providing the rationale for further 
studies. Findings from the phase III JAVELIN Lung 100 
study will help clarify the potential role of avelumab 
monotherapy in the NSCLC treatment landscape.
Author affiliations
1Division of Medical Oncology, The Ohio State University James Cancer Hospital, 
Columbus, Ohio, USA
2Department of Medical Oncology, CHU Sart Tilman Liege and Liege University, 
Liege, Belgium
3Institute for Melanoma Research & Education, California Cancer Associates for 
Research & Excellence, Encinitas, California, USA
4Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida, USA
5Sharp Healthcare, San Diego, California, USA
6Department of Pneumology, Thoracic Oncology, University Hospital Centre Nantes, 
Nantes, France
7Novant Health Oncology Specialists, Winston- Salem, North Carolina, USA
8Internal Medicine, University of California Davis Comprehensive Cancer Center, 
Sacramento, California, USA
9Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
10University of Cincinnati Cancer Institute, Cincinnati, Ohio, USA
11Providence Cancer Center, Portland, Oregon, USA
12Sarah Cannon Research Institute, Nashville, Tennessee, USA
13Henry Ford Medical Center, Detroit, Michigan, USA
14Merck KGaA, Darmstadt, Germany
15Merck Serono Pharmaceutical R&D Co, Beijing, China; an affiliate of Merck KGaA, 
Darmstadt, Germany
16EMD Serono Research & Development Institute, Inc, Billerica, Massachusetts, 
USA; a business of Merck KGaA, Darmstadt, Germany
17Genitourinary Malignancies Branch and Laboratory of Tumor Immunology and 
Biology, Center for Cancer Research, National Cancer Institute, National Institutes of 
Health, Bethesda, Maryland, USA
Twitter James L Gulley @gulleyj1
Acknowledgements The authors thank the patients and their families, 
investigators, co- investigators, and study teams at each of the participating centers 
and at Merck KGaA, Darmstadt, Germany, and EMD Serono, Inc; a business of 
Merck KGaA, Darmstadt, Germany.
Contributors Conception and design: CFV, HJG, DZ, NM, MB, and JLG. Provision 
of study materials or patients: CFV, GJ, EFM, NI, CHR, JB, FLC, KK, JM, JCM, 
MT, DS, and DW. Collection and assembly of data: All authors. Data analysis 
and interpretation: All authors. Manuscript writing: All authors. Final approval of 
manuscript: All authors.
Funding This trial was sponsored by Merck KGaA, Darmstadt, Germany and is 
part of an alliance between Merck KGaA and Pfizer. Medical writing support was 
provided by ClinicalThinking and funded by Merck KGaA and Pfizer.
Competing interests CFV, EFM, NI, and FLC have nothing to disclose. GJ has 
received research funding from Merck KGaA, Novartis, Pfizer, and Roche; personal 
fees from AbbVie, Amgen, AstraZeneca, Bristol- Myers Squibb, Daiichi Sankyo, 
Eli Lilly, Novartis, Pfizer, and Roche; and non- financial support from Amgen, 
AstraZeneca, Bristol Myers Squibb, Eli Lilly, MedImmune, Merck KGaA, Novartis, 
Pfizer, and Roche. CHR owns stock in Pfizer. JB has provided advisory and speaker 
services for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck & 
Co, Roche, and Servier. KK has received research grants from EMD Serono (a 
business of Merck KGaA, Darmstadt, Germany) and Merck & Co; has served on 
advisory boards for EMD Serono and Merck & Co; and has received a honorarium 
from Merck & Co. JM has received research funding from Merck KGaA; research 
funding from Amgen, AstraZeneca, Bristol Myers Squibb, EMD Serono (a business 
of Merck KGaA, Darmstadt, Germany), Incyte, MacroGenics, Merck KGaA, Polynoma 
LLC, and Sanofi. JCM has provided speaker services for Boehringer Ingelheim and 
Merck KGaA, and has received travel expenses from Amgen, Eisai, Merck KGaA, 
and VentiRx Pharmaceuticals. MT has provided advisory and speaker services 
for Bristol Myers Squibb and Eisai; and advisory services for Array BioPharma, 
ArQule, Bayer, Blueprint Medicines, Loxo Oncology, Novartis, and Sanofi Genzyme. 
DS has provided consultancy or advisory services and received research funding 
from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, 
Celgene, Eli Lilly, Foundation Medicine, GlaxoSmithKline, Merck KGaA, Nektar, 
Novartis, Pfizer, Roche/Genentech, and Takeda Oncology; received travel expenses 
from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli 
Lilly, EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Intuitive 
Surgical, Merck KGaA, Perdue Pharma, Pfizer, Roche/Genentech, Sanofi Genzyme, 
Spectrum Pharmaceuticals, and Sysmex; provided consultancy or advisory services 
for Aptitude Health, Evelo Biosciences, Illumina, Moderna, Pharma Mar, and 
Precision Oncology; and received research funding from Acerta Pharma, Aeglea 
Biotherapeutics, ARMO BioSciences, Astellas Pharma, Celldex Therapeutics, Clovis 
Oncology, Daiichi Sankyo, EMD Serono (a business of Merck KGaA, Darmstadt, 
Germany), G1 Therapeutics, GRAIL, Ipsen, Neon Therapeutics, Oncogenex 
Pharmaceuticals, Takeda Oncology, Tesaro, and Transgene, and the University of 
Texas Southwestern Medical Center—Simmons Cancer Center. DW has provided 
advisory services for and received travel expenses from Merck KGaA. HJG is an 
employee of Merck KGaA, Darmstadt, Germany. DZ is an employee of Merck Serono 
Pharmaceutical R&D Co, Beijing, China; a business of Merck KGaA, Darmstadt, 
Germany. NM and MB are employees of EMD Serono, Inc; a business of Merck 
KGaA, Darmstadt, Germany. JLG has received research funding from EMD Serono, 
Inc (a business of Merck KGaA, Darmstadt, Germany).
Patient consent for publication Not required.
Ethics approval The trial was conducted in accordance with the ethics principles 
of the Declaration of Helsinki and the International Council for Harmonization 
Guidelines on Good Clinical Practice. The protocol was approved by the institutional 
review board or independent ethics committee of each center. All patients provided 
written informed consent before enrollment.
Provenance and peer review Not commissioned; externally peer- reviewed.
Data availability statement Data are available upon reasonable request. For all 
new products or new indications approved in both the European Union and the USA 
after January 1, 2014, Merck KGaA, Darmstadt, Germany, will share patient- level 
and study- level data after de- identification, as well as redacted study protocols 
and clinical study reports from clinical trials in patients. These data will be shared 
with qualified scientific and medical researchers, upon researchers’ requests, as 
necessary for conducting legitimate research. Such requests must be submitted 
in writing to the company’s data sharing portal. More information can be found 
at https://www. merckgroup. com/ en/ research/ our- approach- to- research- and- 
development/ healthcare/ clinical- trials/ commitment- responsible- data- sharing. 
html. Where Merck KGaA has a co- research, co- development or co- marketing/co- 
promotion agreement or where the product has been out- licensed, it is recognized 
that the responsibility for disclosure may be dependent on the agreement between 
parties. Under these circumstances, Merck KGaA will endeavor to gain agreement 
to share data in response to requests.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Claire F Verschraegen http:// orcid. org/ 0000- 0001- 6544- 3089
James L Gulley http:// orcid. org/ 0000- 0002- 6569- 2912
REFERENCES
 1 Pai- Scherf L, Blumenthal GM, Li H, et al. FDA approval summary: 
pembrolizumab for treatment of metastatic non- small cell lung 
cancer: first- line therapy and beyond. Oncologist 2017;22:1392–9.
 2 Reck M, Rodríguez- Abreu D, Robinson AG, et al. Pembrolizumab 
versus chemotherapy for PD- L1- positive non- small- cell lung cancer. 
N Engl J Med 2016;375:1823–33.
8 Verschraegen CF, et al. J Immunother Cancer 2020;8:e001064. doi:10.1136/jitc-2020-001064
Open access 
 3 Mok TSK, Wu Y- L, Kudaba I, et al. Pembrolizumab versus 
chemotherapy for previously untreated, PD- L1- expressing, locally 
advanced or metastatic non- small- cell lung cancer (KEYNOTE-042): 
a randomised, open- label, controlled, phase 3 trial. Lancet 
2019;393:1819–30.
 4 Carbone DP, Reck M, Paz- Ares L, et al. First- line nivolumab in 
stage IV or recurrent non- small- cell lung cancer. N Engl J Med 
2017;376:2415–26.
 5 Gandhi L, Rodríguez- Abreu D, Gadgeel S, et al. Pembrolizumab plus 
chemotherapy in metastatic non- small- cell lung cancer. N Engl J 
Med 2018;378:2078–92.
 6 Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first- 
line treatment of metastatic nonsquamous NSCLC. N Engl J Med 
2018;378:2288–301.
 7 West H, McCleod M, Hussein M, et al. Atezolizumab in combination 
with carboplatin plus nab- paclitaxel chemotherapy compared 
with chemotherapy alone as first- line treatment for metastatic 
non- squamous non- small- cell lung cancer (IMpower130): a 
multicentre, randomised, open- label, phase 3 trial. Lancet Oncol 
2019;20:924–37.
 8 Vandeveer AJ, Fallon JK, Tighe R, et al. Systemic immunotherapy 
of non- muscle invasive mouse bladder cancer with avelumab, an 
anti- PD- L1 immune checkpoint inhibitor. Cancer Immunol Res 
2016;4:452–62.
 9 Boyerinas B, Jochems C, Fantini M, et al. Antibody- dependent 
cellular cytotoxicity activity of a novel anti- PD- L1 antibody avelumab 
(MSB0010718C) on human tumor cells. Cancer Immunol Res 
2015;3:1148–57.
 10 Bavencio (avelumab). [Prescibing information]. Rockland, MA: EMD 
Serono, a business of Merck KGaA, Darmstadt, Germany, 2020.
 11 Bavencio (avelumab). [Summary of product characteristics]. 
Darmstadt, Germany: Merck KGaA, 2019.
 12 Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with 
previously treated metastatic or recurrent non- small- cell lung cancer 
(JAVELIN solid tumor): dose- expansion cohort of a multicentre, 
open- label, phase 1b trial. Lancet Oncol 2017;18:599–610.
 13 Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and safety 
of avelumab treatment in patients with advanced unresectable 
mesothelioma: phase 1b results from the JAVELIN solid tumor trial. 
JAMA Oncol 2019;5:351–7.
 14 Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients 
with previously treated metastatic adrenocortical carcinoma: phase 
1b results from the JAVELIN solid tumor trial. J Immunother Cancer 
2018;6:111.
 15 Keilholz U, Mehnert JM, Bauer S, et al. Avelumab in patients with 
previously treated metastatic melanoma: phase 1b results from the 
JAVELIN solid tumor trial. J Immunother Cancer 2019;7:12.
 16 Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in 
patients with advanced solid tumors: a pooled analysis of data from 
the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 
clinical trials. Cancer 2018;124:2010–7.
 17 Reck M, Yang C- H, Postmus PE, et al. JAVELIN lung 100: 
updated design of a phase 3 trial of avelumab vs platinum 
doublet chemotherapy as first- line (1L) treatment for metastatic or 
recurrent PD- L1+ non- small- cell lung cancer (NSCLC). Ann Oncol 
2017;28:abstract 1377TiP:v492.
 18 Mirsadraee S, Oswal D, Alizadeh Y, et al. The 7th lung cancer 
TNM classification and staging system: review of the changes and 
implications. World J Radiol 2012;4:128–34.
 19 Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of 
immune therapy activity in solid tumors: immune- related response 
criteria. Clin Cancer Res 2009;15:7412–20.
 20 Feng Z, Schlichting M, Helwig C, et al. Comparative study of two 
PD- L1 expression assays in patients with non- small cell lung cancer 
(NSCLC). J Clin Oncol 2017;35:e20581.
 21 Tsao MS, Kerr KM, Kockx M, et al. PD- L1 immunohistochemistry 
comparability study in real- life clinical samples: results of blueprint 
phase 2 project. J Thorac Oncol 2018;13:1302–11.
 22 Gulley JL, Spigel DR, Kelly K, et al. Exposure- response and PD- 
L1 expression analysis of second- line avelumab in patients with 
advanced NSCLC: data from the JAVELIN solid tumor trial. J Clin 
Oncol 2017;35:9086.
 23 Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel 
in patients with platinum- treated advanced non- small- cell lung 
cancer (JAVELIN lung 200): an open- label, randomised, phase 3 
study. Lancet Oncol 2018;19:1468–79.
 24 Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first- line 
therapy for patients with PD- L1- positive advanced non- small cell 
lung cancer: a phase 1 trial. Ann Oncol 2017;28:874–81.
 25 Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for 
first- line treatment of advanced non- small- cell lung cancer. J Clin 
Oncol 2016;34:2980–7.
 26 Antonia SJ, Balmanoukian A, Brahmer J, et al. Clinical activity, 
tolerability, and long- term follow- up of durvalumab in patients with 
advanced NSCLC. J Thorac Oncol 2019;14:1794–806.
 27 Grote HJ, Feng Z, Schlichting M, et al. PD- L1 immunohistochemistry 
assay comparison studies in non- small cell lung cancer: 
characterization of the 73-10 assay. J Thorac Oncol 2020;12:208–22.
 28 Spigel D, de Marinis F, Giaccone G, et al. IMpower110: interim overall 
survival (OS) analysis of a phase III study of atezolizumab (atezo) vs 
platinum- based chemotherapy (chemo) as first- line (1L) treatment (tx) 
in PD- L1–selected NSCLC. Ann Oncol 2019;30(Suppl 5):LBA78.
 29 Rizvi NA, Chul Cho B, Reinmuth N, et al. Durvalumab with or 
without tremelimumab vs platinum- based chemotherapy as first- line 
treatment for metastatic non- small cell lung cancer: MYSTIC. Ann 
Oncol 2018;29(suppl_10):LBA6.
 30 Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: 
non- small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 
2018;16:807–21.
 31 Planchard D, Popat S, Kerr K, et al. Metastatic non- small cell lung 
cancer: ESMO clinical practice guidelines for diagnosis, treatment 
and follow- up. Ann Oncol 2018;29:iv192–237.
